Contact the Editorial Desk

Editorial correspondence

Correspondence on the research record is welcome: a citation quoted inaccurately, a regulatory reference that has changed (the FDA drug status of thymosin alpha-1 compounds keeps shifting), or a peer-reviewed study on thymulin or thymosin alpha-1 that should join the references page. Corrections that improve the accuracy of the briefing are the most useful messages it receives.

The most actionable notes specify three things: the page they refer to, the exact passage in question, and the supporting citation — a DOI or PubMed ID wherever possible. That lets a proposed change be checked against the primary source quickly.

Editorial mailbox: editors@peptidecarenow.com

What this desk cannot do

So that no message goes unanswered for the wrong reason, several things sit outside what this briefing can address. Peptide Care Now reads the literature; it is not a clinic or a vendor, so it cannot:

• Advise on, recommend, or comment on human use of any peptide covered here.
• Suggest a dose, schedule, or route of administration for any individual.
• Diagnose a condition or judge whether a particular research finding applies to a particular person.
• Sell, source, recommend, or help locate any compound from any supplier.
• Read the 2025 TESTS null result ^[8] — or any other finding — as guidance for an individual's health decisions; that is a conversation for a licensed clinician.

Anyone seeking medical guidance should consult a licensed clinician in their own jurisdiction. Editorial correspondence is read carefully, but replies are not guaranteed and may be delayed; the mailbox is watched intermittently.